Cargando…

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2

Monoclonal antibodies targeting the SARS-CoV-2 spike (S) glycoprotein neutralize infection and are efficacious for the treatment of mild-to-moderate COVID-19. However, SARS-CoV-2 variants have emerged that partially or fully escape monoclonal antibodies in clinical use. Notably, the BA.2 sublineage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lianghui, Narayanan, Krishna K., Cooper, Laura, Chan, Kui K., Devlin, Christine A., Aguhob, Aaron, Shirley, Kristie, Rong, Lijun, Rehman, Jalees, Malik, Asrar B., Procko, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978935/ https://www.ncbi.nlm.nih.gov/pubmed/35378764 http://dx.doi.org/10.1101/2022.03.28.486075

Ejemplares similares

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2
por: Zhang, Lianghui, et al.
Publicado: (2022)

Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants
por: Zhang, Lianghui, et al.
Publicado: (2022)

An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant
por: Zhang, Haoran, et al.
Publicado: (2022)

Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2
por: Golcuk, Mert, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Computationally engineered ACE2 decoy binds with nanomolar affinity with the SARS-CoV-2 spike protein
por: Islam, Mohammad S., et al.
Publicado: (2022)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
por: Torres, Carolina, et al.
Publicado: (2023)

Machine learning guided design of high affinity ACE2 decoys for SARS-CoV-2 neutralization
por: Chan, Matthew C., et al.
Publicado: (2021)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
por: Kimura, Izumi, et al.
Publicado: (2022)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
por: Tamura, Tomokazu, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
por: Huo, Jiandong, et al.
Publicado: (2023)

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
por: Moulana, Alief, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients
por: Pedersen, Rune M., et al.
Publicado: (2022)

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
por: Touret, Franck, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
por: Muik, Alexander, et al.
Publicado: (2022)

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
por: Kang, Sung-Woon, et al.
Publicado: (2023)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
por: Huo, Jiandong, et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
por: Shuai, Huiping, et al.
Publicado: (2023)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
por: Diem, Gabriel, et al.
Publicado: (2023)

Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
por: Kumar, Sanjeev, et al.
Publicado: (2022)

Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England
por: Elliott, Paul, et al.
Publicado: (2022)

Structural characteristics of the SARS-CoV-2 Omicron lineages BA.1 and BA.2 virions
por: Ma, Xiaoyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0r13prao1hfgd5hetmn1qlhkeb